	US 11,897,955 B2
	Monoclonal antibody binding to TIGIT antigen, preparation method and use thereof
Qunmin Zhou, Suzhou (CN); Weiwei Sun, Suzhou (CN); Zui Chen, Suzhou (CN); Xiaoxiao Ma, Suzhou (CN); Jinling Fan, Suzhou (CN); and Hongqun Hu, Suzhou (CN)
Assigned to ACROIMMUNE BIOTECH CO., LTD., Guangzhou (CN)
Appl. No. 17/915,109
Filed by ACROIMMUNE BIOTECH CO., LTD., Guangzhou (CN)
PCT Filed Jul. 15, 2020, PCT No. PCT/CN2020/102091 § 371(c)(1), (2) Date Mar. 20, 2023, PCT Pub. No. WO2021/217893, PCT Pub. Date Nov. 4, 2021.
Claims priority of application No. 202010353714.6 (CN), filed on Apr. 29, 2020.
Prior Publication US 2023/0272064 A1, Aug. 31, 2023
Int. Cl. C07K 16/02 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C12N 15/85 (2006.01)

CPC C07K 16/28 (2013.01) [A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C12N 15/85 (2013.01); C07K 2317/76 (2013.01); C12N 2800/107 (2013.01)]

20 Claims

1. A monoclonal antibody or a derivative thereof binding to a TIGIT antigen, comprising a first variable region and a second variable region,

wherein the first variable region is an antibody light chain variable region comprising complementarity-determining regions CDR1, CDR2, and CDR3 having amino acid sequences as set forth in SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11, respectively; and

wherein the second variable region is an antibody heavy chain variable region comprising complementarity-determining regions CDR1, CDR2, and CDR3 having amino acid sequences as set forth in SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16, respectively.